[{"NetIncomeLossConverted_1_Q1_USD":1355300000.0,"StockholdersEquityConverted_0_Q1_USD":7099300000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":908800000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_1_Q1_USD":1697400000.0,"EarningsPerShareDiluted_1_Q1_USD":1.49,"StockholdersEquity_0_Q1_USD":6898700000.0,"Assets_0_Q1_USD":46838300000.0,"RevenuesConverted_1_Q1_USD":6805600000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":912400000.0,"EarningsPerShareBasic_1_Q1_USD":1.49,"Ticker":"LLY","CIK":"59478","name":"ELI LILLY & CO","OfficialName":"Eli Lilly and Company Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"282857000000.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"SP500","filed":"20210430"}]